Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of AGMB-447 in idiopathic pulmonary fibrosis
2026-526404-71-00Phase 2Authorised
- Sponsor
- Agomab Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Inspiria with Placebo (2 arms). Primary endpoint: Change from baseline in forced vital capacity. Planned start Oct 2026; status: authorised.
02
Drugs
AGMB-447
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2026-526404-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526404-71-00.